Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:morgag04

Total Results:

677


Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis

Andersen, Jens Peter; Bøgsted, Martin; Dybkær, Karen; Mellqvist, Ulf-Henrik; Morgan, Gareth J; Goldschmidt, Hartmut; Dimopoulos, Meletios A; Einsele, Hermann; San Miguel, Jesús; Palumbo, Antonio; Sonneveld, Pieter; Johnsen, Hans Erik
BACKGROUND:International collaborative research is a mechanism for improving the development of disease-specific therapies and for improving health at the population level. However, limited data are available to assess the trends in research output related to orphan diseases. METHODS AND FINDINGS/RESULTS:We used bibliometric mapping and clustering methods to illustrate the level of fragmentation in myeloma research and the development of collaborative efforts. Publication data from Thomson Reuters Web of Science were retrieved for 2005-2009 and followed until 2013. We created a database of multiple myeloma publications, and we analysed impact and co-authorship density to identify scientific collaborations, developments, and international key players over time. The global annual publication volume for studies on multiple myeloma increased from 1,144 in 2005 to 1,628 in 2009, which represents a 43% increase. This increase is high compared to the 24% and 14% increases observed for lymphoma and leukaemia. The major proportion (>90% of publications) was from the US and EU over the study period. The output and impact in terms of citations, identified several successful groups with a large number of intra-cluster collaborations in the US and EU. The US-based myeloma clusters clearly stand out as the most productive and highly cited, and the European Myeloma Network members exhibited a doubling of collaborative publications from 2005 to 2009, still increasing up to 2013. CONCLUSION AND PERSPECTIVE/CONCLUSIONS:Multiple myeloma research output has increased substantially in the past decade. The fragmented European myeloma research activities based on national or regional groups are progressing, but they require a broad range of targeted research investments to improve multiple myeloma health care.
PMCID:4309532
PMID: 25629620
ISSN: 1932-6203
CID: 3648542

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Rawstron, Andy C; Gregory, Walter M; de Tute, Ruth M; Davies, Faith E; Bell, Sue E; Drayson, Mark T; Cook, Gordon; Jackson, Graham H; Morgan, Gareth J; Child, J Anthony; Owen, Roger G
The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10(-4)) after treatment is an independent predictor of progression-free survival (PFS), but not always of overall survival (OS). However, MRD level is a continuous variable, and the predictive value of the depth of tumor depletion was evaluated in 397 patients treated intensively in the Medical Research Council Myeloma IX study. There was a significant improvement in OS for each log depletion in MRD level (median OS was 1 year for ≥10%, 4 years for 1% to <10%, 5.9 years for 0.1% to <1%, 6.8 years for 0.01% to <0.1%, and more than 7.5 years for <0.01% MRD). MRD level as a continuous variable determined by flow cytometry independently predicts both PFS and OS, with approximately 1 year median OS benefit per log depletion. The trial was registered at www.isrctn.com as #68454111.
PMCID:4375716
PMID: 25645353
ISSN: 1528-0020
CID: 3648562

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

Walker, Brian A; Wardell, Christopher P; Murison, Alex; Boyle, Eileen M; Begum, Dil B; Dahir, Nasrin M; Proszek, Paula Z; Melchor, Lorenzo; Pawlyn, Charlotte; Kaiser, Martin F; Johnson, David C; Qiang, Ya-Wei; Jones, John R; Cairns, David A; Gregory, Walter M; Owen, Roger G; Cook, Gordon; Drayson, Mark T; Jackson, Graham H; Davies, Faith E; Morgan, Gareth J
We have sequenced 463 presenting cases of myeloma entered into the UK Myeloma XI study using whole exome sequencing. Here we identify mutations induced as a consequence of misdirected AID in the partner oncogenes of IGH translocations, which are activating and associated with impaired clinical outcome. An APOBEC mutational signature is seen in 3.8% of cases and is linked to the translocation-mediated deregulation of MAF and MAFB, a known poor prognostic factor. Patients with this signature have an increased mutational load and a poor prognosis. Loss of MAF or MAFB expression results in decreased APOBEC3B and APOBEC4 expression, indicating a transcriptional control mechanism. Kataegis, a further mutational pattern associated with APOBEC deregulation, is seen at the sites of the MYC translocation. The APOBEC mutational signature seen in myeloma is, therefore, associated with poor prognosis primary and secondary translocations and the molecular mechanisms involved in generating them.
PMCID:4568299
PMID: 25904160
ISSN: 2041-1723
CID: 3648582

Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma

Di Martino, Maria Teresa; Guzzi, Pietro Hiram; Caracciolo, Daniele; Agnelli, Luca; Neri, Antonino; Walker, Brian A; Morgan, Gareth J; Cannataro, Mario; Tassone, Pierfrancesco; Tagliaferri, Pierosandro
Multiple Myeloma (MM) is a malignancy characterized by the hyperdiploid (HD-MM) and the non-hyperdiploid (nHD-MM) subtypes. To shed light within the molecular architecture of these subtypes, we used a novel integromics approach. By annotated MM patient mRNA/microRNA (miRNA) datasets, we investigated mRNAs and miRNAs profiles with relation to changes in transcriptional regulators expression. We found that HD-MM displays specific gene and miRNA expression profiles, involving the Signal Transducer and Activator of Transcription (STAT)3 pathway as well as the Transforming Growth Factor-beta (TGFβ) and the transcription regulator Nuclear Protein-1 (NUPR1). Our data define specific molecular features of HD-MM that may translate in the identification of novel relevant druggable targets.
PMCID:4662480
PMID: 26056083
ISSN: 1949-2553
CID: 3648612

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway

Smith, Emma M; Zhang, Lei; Walker, Brian A; Davenport, Emma L; Aronson, Lauren I; Krige, David; Hooftman, Leon; Drummond, Alan H; Morgan, Gareth J; Davies, Faith E
There is a growing body of evidence supporting the use of epigenetic therapies in the treatment of multiple myeloma. We show the novel HDAC inhibitor CHR-3996 induces apoptosis in myeloma cells at concentrations in the nanomolar range and with apoptosis mediated by p53 and caspase pathways. In addition, HDAC inhibitors are highly synergistic, both in vitro and in vivo, with the aminopeptidase inhibitor tosedostat (CHR-2797). We demonstrate that the basis for this synergy is a consequence of changes in the levels of NFκB regulators BIRC3/cIAP2, A20, CYLD, and IκB, which were markedly affected by the combination. When co-administered the HDAC and aminopeptidase inhibitors caused rapid nuclear translocation of NFκB family members p65 and p52, following activation of both canonical and non-canonical NFκB signalling pathways. The subsequent up-regulation of inhibitors of NFκB activation (most significantly BIRC3/cIAP2) turned off the cytoprotective effects of the NFκB signalling response in a negative feedback loop. These results provide a rationale for combining HDAC and aminopeptidase inhibitors clinically for the treatment of myeloma patients and support the disruption of the NFκB signalling pathway as a therapeutic strategy.
PMCID:4627310
PMID: 26015393
ISSN: 1949-2553
CID: 3648602

Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum Stress

Bright, Michael D; Itzhak, Daniel N; Wardell, Christopher P; Morgan, Gareth J; Davies, Faith E
The unfolded protein response (UPR) remediates endoplasmic reticulum (ER) stress. IRE1, a component of the UPR, senses misfolded protein and cleaves XBP1 mRNA, which is ligated to code for the prosurvival transcription factor. IRE1 also cleaves other mRNAs preceding their degradation, termed regulated IRE1-dependent mRNA decay (RIDD). It has been reported that RIDD may be involved in cell viability under stress and therefore may contribute to cancer cell viability. To investigate RIDD targets that may have functional relevance in cell survival, we identified conserved RIDD targets containing stringent IRE1 RNase target sequences. Using a systematic bioinformatics approach with quantitative-PCR (qPCR) validation, we show that only BLOC1S1 is consistently a RIDD target in all systems tested. Using cancer cell lines, we show that BLOC1S1 is specifically cleaved by IRE1 at guanine 444, but only under conditions of IRE1 hyperactivation. BLOC1S1 cleavage is temporally separate from XBP1 splicing, occurring after depletion of unspliced XBP1. Expression of an uncleavable BLOC1S1 mutant or inhibition of RIDD using an IRE1 RNase inhibitor did not affect cellular recovery from acute ER stress. These data demonstrate that although hyperactivated IRE1 specifically cleaves BLOC1S1, this cleavage event and RIDD as a whole are dispensable for cell viability under acute stress.
PMCID:4438243
PMID: 25870107
ISSN: 1098-5549
CID: 3648572

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma

Sawyer, Jeffrey R; Tian, Erming; Heuck, Christoph J; Johann, Donald J; Epstein, Joshua; Swanson, Charles M; Lukacs, Janet L; Binz, Regina Lichti; Johnson, Marian; Sammartino, Gael; Zangari, Maurizio; Davies, Faith E; van Rhee, Frits; Morgan, Gareth J; Barlogie, Bart
Multiple myeloma is a B-cell malignancy stratified in part by cytogenetic abnormalities, including the high-risk copy number aberrations (CNAs) of +1q21 and 17p(-). To investigate the relationship between 1q21 CNAs and DNA hypomethylation of the 1q12 pericentromeric heterochromatin, we treated in vitro peripheral blood cultures of 5 patients with balanced constitutional rearrangements of 1q12 and 5 controls with the hypomethylating agent 5-azacytidine. Using G-banding, fluorescence in situ hybridization, and spectral karyotyping, we identified structural aberrations and copy number gains of 1q21 in the treated cells similar to those found in patients with cytogenetically defined high-risk disease. Aberrations included 1q12 triradials, amplifications of regions juxtaposed to 1q12, and jumping translocations 1q12. Strikingly, all 5 patients with constitutional 1q12 rearrangements showed amplifications on the derivative chromosomes distal to the inverted or translocated 1q12 region, including MYCN in 1 case. At the same time, no amplification of the 1q21 region was found when the 1q12 region was inverted or absent. These findings provide evidence that the hypomethylation of the 1q12 region can potentially amplify any genomic region juxtaposed to it and mimic CNAs found in the bone marrow of patients with high-risk disease.
PMCID:4463736
PMID: 25943786
ISSN: 1528-0020
CID: 3648592

Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors

Tornatore, Laura; Sandomenico, Annamaria; Raimondo, Domenico; Low, Caroline; Rocci, Alberto; Tralau-Stewart, Cathy; Capece, Daria; D'Andrea, Daniel; Bua, Marco; Boyle, Eileen; van Duin, Mark; Zoppoli, Pietro; Jaxa-Chamiec, Albert; Thotakura, Anil K; Dyson, Julian; Walker, Brian A; Leonardi, Antonio; Chambery, Angela; Driessen, Christoph; Sonneveld, Pieter; Morgan, Gareth; Palumbo, Antonio; Tramontano, Anna; Rahemtulla, Amin; Ruvo, Menotti; Franzoso, Guido
Constitutive NF-κB signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-κB-targeting strategies lack cancer cell specificity. Here, we identify the interaction between the NF-κB-regulated antiapoptotic factor GADD45β and the JNK kinase MKK7 as a therapeutic target in MM. Using a drug-discovery strategy, we developed DTP3, a D-tripeptide, which disrupts the GADD45β/MKK7 complex, kills MM cells effectively, and, importantly, lacks toxicity to normal cells. DTP3 has similar anticancer potency to the clinical standard, bortezomib, but more than 100-fold higher cancer cell specificity in vitro. Notably, DTP3 ablates myeloma xenografts in mice with no apparent side effects at the effective doses. Hence, cancer-selective targeting of the NF-κB pathway is possible and, at least for myeloma patients, promises a profound benefit.
PMID: 25314077
ISSN: 1878-3686
CID: 3695052

European perspective on multiple myeloma treatment strategies in 2014

Ludwig, Heinz; Sonneveld, Pieter; Davies, Faith; Bladé, Joan; Boccadoro, Mario; Cavo, Michele; Morgan, Gareth; de la Rubia, Javier; Delforge, Michel; Dimopoulos, Meletios; Einsele, Hermann; Facon, Thierry; Goldschmidt, Hartmut; Moreau, Philippe; Nahi, Hareth; Plesner, Torben; San-Miguel, Jesús; Hajek, Roman; Sondergeld, Pia; Palumbo, Antonio
The treatment of multiple myeloma has undergone significant changes and has resulted in the achievement of molecular remissions, the prolongation of remission duration, and extended survival becoming realistic goals, with a cure being possible in a small but growing number of patients. In addition, nowadays it is possible to categorize patients more precisely into different risk groups, thus allowing the evaluation of therapies in different settings and enabling a better comparison of results across trials. Here, we review the evidence from clinical studies, which forms the basis for our recommendations for the management of patients with myeloma. Treatment approaches depend on "fitness," with chronological age still being an important discriminator for selecting therapy. In younger, fit patients, a short three drug-based induction treatment followed by autologous stem cell transplantation (ASCT) remains the preferred option. Consolidation and maintenance therapy are attractive strategies not yet approved by the European Medicines Agency, and a decision regarding post-ASCT therapy should only be made after detailed discussion of the pros and cons with the individual patient. Two- and three-drug combinations are recommended for patients not eligible for transplantation. Treatment should be administered for at least nine cycles, although different durations of initial therapy have only rarely been compared so far. Comorbidity and frailty should be thoroughly assessed in elderly patients, and treatment must be adapted to individual needs, carefully selecting appropriate drugs and doses. A substantial number of new drugs and novel drug classes in early clinical development have shown promising activity. Their introduction into clinical practice will most likely further improve treatment results.
PMCID:4122482
PMID: 25063227
ISSN: 1549-490x
CID: 3695042

Updates to the guidelines for the diagnosis and management of multiple myeloma [Letter]

Pratt, Guy; Jenner, Matthew; Owen, Roger; Snowden, John A; Ashcroft, John; Yong, Kwee; Feyler, Sylvia; Morgan, Gareth; Cavenagh, Jamie; Cook, Gordon; Low, Eric; Stern, Simon; Behrens, Judith; Davies, Faith; Bird, Jennifer
PMID: 24801672
ISSN: 1365-2141
CID: 3695022